🎯 Schemes & WelfareMAINS · GS2.13 · GS2.9

Cancer drug margins capped at 30 per cent, against a measured mark-up of 170

Non-scheduled anti-cancer medicines come under a trade margin cap expected to cut prices up to 70 per cent and save patients Rs 2,500 crore a year.

What happened

Margins on non-scheduled anti-cancer drugs capped at 30 per cent of maximum retail price.
Expected to cut prices by up to 70 per cent and save patients Rs 2,500 crore annually.
NPPA found an average mark-up of about 170 per cent, reaching 700 per cent or more in some cases, with prices varying between retail, hospital and online pharmacies.
An expert committee under the Directorate General of Health Services will finalise the medicine list; NPPA will decide and notify.
The February 2019 precedent capped 42 drugs under Paragraph 19 of the DPCO, 2013, cutting MRPs up to 91 per cent and saving Rs 984 crore across 526 brands.

For Prelims

DPCO, 2013: the Drugs (Prices Control) Order, issued under the Essential Commodities Act, 1955. Medicines in the National List of Essential Medicines are scheduled and get a ceiling price; everything else is non-scheduled.
Paragraph 19: the DPCO provision giving the government extraordinary powers in public interest to fix the price of any drug, including a non-scheduled one. It is the legal hook for both the 2019 and the present intervention.
Ceiling price against trade margin cap: a ceiling price fixes what the medicine may cost; a margin cap fixes how much the distribution chain may add above the price at first point of sale. The second regulates distributors and retailers rather than manufacturers.
NPPA: the National Pharmaceutical Pricing Authority, set up in 1997 under the Department of Pharmaceuticals, which fixes and revises prices and monitors availability.
Non-scheduled formulations: manufacturers may raise prices by up to 10 per cent a year, which is why medicines outside the essential list drift upward without any regulatory event.
Out-of-pocket expenditure: the share of health spending paid directly by households. India’s share has fallen over the past decade but remains high, and medicines are the largest single component of it.
Why cancer specifically: the drugs are expensive, the course is long, substitution is clinically constrained, and demand is price-inelastic - a patient will pay what is asked. Those are the conditions under which a margin cap, rather than competition, is the available remedy.
Jan Aushadhi: the parallel instrument - generic medicines sold through Pradhan Mantri Bhartiya Janaushadhi Pariyojana outlets - which lowers prices by supplying alternatives rather than by regulating margins.

For UPSC: A rare case of a price intervention published with the evidence that justified it and a prior round to check it against. Deploy it on drug price regulation and the DPCO, on out-of-pocket health expenditure, on regulators and market failure, and on the general question of when a government should fix a price rather than increase competition.

What it is NOT: The list of covered medicines does not yet exist - an expert committee will finalise it and NPPA must still notify, so nothing is in force today and no date is given. The Rs 2,500 crore saving is a projection with no method shown, and no count of medicines or brands to be covered, where the 2019 round specified 42 drugs and 526 brands. No figure for current out-of-pocket cancer spending against which the saving could be read. Nothing on enforcement: a margin cap needs price-to-stockist data to police, and the release does not say how compliance will be verified. And nothing on the hospital pharmacy channel, which it names as a source of price variation.

For Mains

Syllabus: GS2.13 · GS2.9 · Linkage L1

Anchor

The government has approved a cap limiting trade margins on non-scheduled anti-cancer medicines to 30 per cent of the maximum retail price, expected to reduce prices by up to 70 per cent and save patients Rs 2,500 crore a year. An expert committee under the Directorate General of Health Services will finalise which medicines are covered, and the National Pharmaceutical Pricing Authority will notify.

Substantiation (data)

The intervention rests on measurement rather than assertion. NPPA’s analysis of market data found an average mark-up of approximately 170 per cent on these medicines, reaching 700 per cent or more in some cases, with prices differing between retail, hospital and online pharmacies. Maharashtra, Rajasthan and Karnataka had raised the issue. The 2019 round under Paragraph 19 of the DPCO capped margins on 42 non-scheduled anti-cancer drugs, cut MRPs by up to 91 per cent, and saved a reported Rs 984 crore across 526 brands.

Position

A 170 per cent average mark-up means the distribution chain adds more than the medicine costs at first sale, and that is not a competitive outcome - it is what happens when the buyer cannot shop, cannot substitute and cannot wait. Capping the margin rather than the price is the precise instrument for it: it leaves the manufacturer’s price alone, so the incentive to produce is untouched, and squeezes only the part of the chain where the evidence showed the excess. Requiring manufacturers to maintain output closes the obvious escape.

Counterpoint

Nothing is in force. The list does not exist, the committee has not reported, NPPA has not notified, and no date is attached to any of those steps - so a release announcing savings of Rs 2,500 crore is announcing an intention. The saving itself is a projection with no method published, and where the 2019 round named 42 drugs and 526 brands, this one names no number at all. Enforcement is the harder gap: policing a margin requires visibility of the price at every point of sale, and the release says nothing about how that will be obtained.

Way forward

The 2019 round is the right benchmark and should be reported against: savings actually realised, price change by brand, and whether any capped medicine went out of supply. Publishing that before the new cap takes effect would establish whether the instrument works as claimed. The hospital pharmacy channel also needs addressing directly, since the release identifies it as a site of price variation and a margin cap set on MRP does not reach the hospital’s own dispensing arrangements.

Conclusion

The right instrument, aimed at a documented excess, in a market where the patient has no bargaining power at all. The measurement behind it is the part worth keeping - 170 per cent on average, 700 per cent at the extreme - and the part still missing is the notification that would make any of it real.

Deploys into: Drug price regulation and the DPCO · Out-of-pocket health expenditure · Regulators and market failure · Price control against competition as policy instruments

Ministry of Chemicals and Fertilizers · 2026-10-08 · PRID 2321092 · PIB source ↗